New approaches to the treatment of the flavivirus infections

Cover Page
  • Authors: Morozova O.V.1, Isaeva E.I.1, Viazov S.O.2
  • Affiliations:
    1. “The D.I. Ivanovsky Institute of Virology” Federal State Budgetary Institution “Federal Research Centre for Epidemiology and Microbiology named after the honorary academician N.F. Gamaleya” of the Ministry of Health of the Russian Federation
    2. Virology Institute of University Hospital
  • Issue: Vol 60, No 6 (2015)
  • Pages: 5-9
  • Section: REVIEWS
  • URL:
  • ID: 359

Cite item


Since spontaneous mutagenesis and quasi-species rearrangements of the ma-containing viruses, as well as an absence of both viral and cellular RNA reparation systems, causes resistance to originally effective antiviral drugs, combination therapy with nucleoside and non-nucleoside inhibitors of the viral enzymes in combination with immunomodulators is recommended. The use of specific immunoglobulins does not result in complete elimination of the flaviviruses but rather in possible antibody-dependent enhancement of the flavivirus infection by means of increased penetration of complexes of virions with specific antibodies into cells with receptors for Fc-fragments of immunoglobulins.

About the authors

O. V. Morozova

“The D.I. Ivanovsky Institute of Virology” Federal State Budgetary Institution “Federal Research Centre for Epidemiology and Microbiology named after the honorary academician N.F. Gamaleya” of the Ministry of Health of the Russian Federation

Author for correspondence.

Olga Morozova, MD,PhD, ScD

123098, Moscow

Russian Federation

E. I. Isaeva

“The D.I. Ivanovsky Institute of Virology” Federal State Budgetary Institution “Federal Research Centre for Epidemiology and Microbiology named after the honorary academician N.F. Gamaleya” of the Ministry of Health of the Russian Federation

123098, Moscow Russian Federation

S. O. Viazov

Virology Institute of University Hospital

Essen Germany


  1. Tong J., Wang Y., Lu Y. New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy. J. Zhejiang Univ. Sci. B. 2012; 13 (1): 56–82.
  2. Baier A. Flavivirus infections and poteintial targets for antiviral therapy. In: Ruzek D., ed. Flavivirus encephalitis. Intech, Croatia; 2011: 89–104.
  3. Chambers T.J., Weir R.C., Grakoui A., McCourt D.W., Bazan J.F., Fletterick R.J. et al. Evidence that the N-terminal domain of nonstructural protein NS3 from yellow fever virus is a serine protease responsible for site-specific cleavages in the viral polyprotein. Proc. Natl. Acad. Sci. U S A. 1990; 87 (22): 8898–902.
  4. Gritsun T.S., Lashkevich V.A., Gould E.A. Tick-borne encephalitis. Antiviral Res. 2003; 57 (1–2): 129–46.
  5. Mansfield K.L., Johnson N., Phipps L.P., Stephenson J.R., Fooks A.R., Solomon T. Tick-borne encephalitis virus – a review of an emerging zoonosis. J. Gen. Virol. 2009; 90 (Pt 8): 1781–94.
  6. Poordad F., McCone J.Jr., Bacon B.R., Bruno S., Manns M.P., Sulkowski M.S. et al. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 364 (13): 1195–206.
  7. Lee E., Lobigs M. Substitutions at the putative receptor-binding site of an encephalitic flavivirus alter virulence and host cell tropism and reveal a role for glycosaminoglycans in entry. J. Virol. 2000; 74 (19): 8867–75.
  8. Lee E., Lobigs M. Mechanism of virulence attenuation of glycosaminoglycan-binding variants of Japanese encephalitis virus and Murray Valley encephalitis virus. J. Virol. 2002; 76 (10): 4901–11.
  9. Robinson M.J., Sancho D., Slack E.C., LeibundGut-Landmann S., Reise Sousa C. Myeloid C-type lectins in innate immunity. Nat. Immunol. 2006; 7 (12): 1258–65.
  10. De Clercq E. Antiviral agents: characteristic activity spectrum depending on the molecular target with which they interact. Adv. Virus Res. 1993; 42: 1–55.
  11. De Clercq E. Highlights in antiviral drug research: antivirals at the horizon. Med. Res. Rev. 2013; 33 (6): 1215–48.
  12. Wu S.F., Lee C.J., Liao C.L., Dwek R.A., Zitzmann N., Lin Y.L. Antiviral effects of an iminosugar derivative on flavivirus infections. J. Virol. 2002; 76 (8): 3596–604.
  13. Borowski P., Niebuhr A., Schmitz H., Hosmane R.S., Bretner M., Siwecka M.A. et al. NTPase/helicase of Flaviviridae: inhibitors and inhibition of the enzyme. Acta Biochim. Pol. 2002; 49 (3): 597–614.
  14. Morozova O.V., Safronov I.V., Bahvalova V.N., Dobrikov M.I. Affinity labelling of the tick-borne encephalitis virus RNA replicase proteins by 4-N-exo-base-sustituted photoreactive CTP analogs. Bioorg. Med. Chem. Lett. 1998; 8 (7): 787–92.
  15. Morozova O.V., Safronov I.V. Viral protein functions study by affinity modification. Mini Rev. Med. Chem. 2001; 1 (3): 283–91.
  16. Thomas D.B. Viruses and the cellular immune response. New York, Basel, Hong Kong; 1993.
  17. Ploss A., Dubuisson J. New advances in the molecular biology of hepatitis C virus infection: towards the identification of new targets. Gut. 2012; 61: 25–35.
  18. Büchler S, Bartenschlager R. New targets for antiviral therapy of chronic hepatitis C. Liver Int. 2012; 32 (Suppl. 1): 9–16.
  19. Schaeffer E.A., Chung R.T. Anti-hepatitis C virus drugs in development. Gastroenterology. 2012; 142 (6): 1340–50.
  20. Chopp S., Vanderwall R., Hult A., Klepser M. Simeprevir and sofospuvir for treatment of hepatitis C infection. Am. J. Health Syst. Pharm. 2015; 72 (17): 1445–55.
  21. Jacobson I.M., Dore G.J., Foster G.R., Fried M.W., Radu M., Rafalsky V.V. et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treaement-naïve patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, doubleblind, placebo-controlled trial. Lancet. 2014; 384 (9941): 403–13.
  22. Guedj J., Pang P.S., Denning J., Rodriguez-Torres M., Lawitz E., Symonds W., Perelson A.S. Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938. Antivir. Ther. 2014; 19 (2): 211–20.
  23. Liu M., Tuttle M., Gao M., Lemm J.A. Potency and resistance analysis of hepatitis C virus NS5B polymerase inhibitor BMS-791325 on all major genotypes. Antimicrob. Agents Chemother. 2014;58 (12): 7416–23.
  24. Wang C., Sun J.H., O’Boyle D.R. 2nd, Nower P., Valera L., Roberts S. et al. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir. Antimicrob. Agents Chemother. 2013; 57 (5): 2054–65.
  25. Salloum S., Tai A.W. Treating hepatitis C infection by targeting the host. Transl. Res. 2012; 159 (6): 421–9.
  26. Stahla-Beek H.J., April D.G., Saeedi B.J., Hannah A.M., Keenan S.M., Geiss B.J. Identification of a novel antiviral inhibitor of the flavivirus guanylyltransferase enzyme. J. Virol. 2012; 86 (16): 8730–9.
  27. Peiris J.S., Porterfield J.S. Antibody-mediated enhancement of flavivirus replication in macrophage cell lines. Nature. 1979; 282 (5738): 509–11.
  28. Phillpotts R.J., Stephenson J.R., Porterfield J.S. Antibody-dependent enhancement of tick-borne encephalitis virus infectivity. J. Gen.Virol. 1985; 66 (8): 1831–7.
  29. Баринский И.Ф., Лазаренко А.А., Алимбарова Л.М., Давыдова А.А. Эффективность сочетанного применения иммуномодуляторов и вакцины при клещевом энцефалите в эксперименте. Вопросы вирусологии. 2011; 56 (4): 45–7.
  30. Kampmann T., Yennamalli R., Campbell P., Stoermer M.J., Fairlie D.P., Kobe B. et al. In silico screening of small molecule libraries using the dengue virus envelope E protein has identified compounds with antiviral activity against multiple flaviviruses. Antiviral Res. 2009; 84 (3): 234–41.

Copyright (c) 2015 Morozova O.V., Isaeva E.I., Viazov S.O.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-77676 от 29.01.2020.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies